Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients
Cucchiari, David (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Egri, Natalia (Hospital Clínic i Provincial de Barcelona)
Bodro, Marta (Hospital Clínic i Provincial de Barcelona)
Herrera, Sabina (Hospital Clínic i Provincial de Barcelona)
Del Risco-Zevallos, Jimena (Hospital Clínic i Provincial de Barcelona)
Casals-Urquiza, Joaquim (Hospital Clínic i Provincial de Barcelona)
Cofan, Frederic (Hospital Clínic i Provincial de Barcelona)
Moreno Camacho, Asunción (Hospital Clínic i Provincial de Barcelona)
Rovira, Jordi (Red de Investigación Renal (REDINREN))
Banon-Maneus, Elisenda (Red de Investigación Renal (REDINREN))
Ramirez-Bajo, Maria J.. (Red de Investigación Renal (REDINREN))
Ventura-Aguiar, Pedro (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Pérez-Olmos, Anna (Hospital Clínic i Provincial de Barcelona)
Garcia-Pascual, Marta (Hospital Clínic i Provincial de Barcelona)
Pascal, Mariona (Instituto de Salud Carlos III)
Vilella, Anna (Hospital Clínic i Provincial de Barcelona)
Trilla, Antoni (Hospital Clínic i Provincial de Barcelona)
Ríos, José (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Palou, Eduard (Hospital Clínic i Provincial de Barcelona)
Juan, Manel (Hospital Clínic i Provincial de Barcelona)
Bayés Genís, Beatriu (Hospital Clínic i Provincial de Barcelona)
Diekmann, Fritz (Red de Investigación Renal (REDINREN))

Data:	2021
Resum:	According to preliminary data, seroconversion after mRNA SARS-CoV-2 vaccination might be unsatisfactory in Kidney Transplant Recipients (KTRs). However, it is unknown if seronegative patients develop at least a cellular response that could offer a certain grade of protection against SARS-CoV-2. To answer this question, we prospectively studied 148 recipients of either kidney (133) or kidney-pancreas (15) grafts with assessment of IgM/IgG spike (S) antibodies and ELISpot against the nucleocapside (N) and the S protein at baseline and two weeks after receiving the second dose of the mRNA-1273 (Moderna) vaccine. At baseline, 31 patients (20. 9%) had either IgM/IgG or ELISpot positivity and were considered to be SARS-CoV-2-pre-immunized, while 117 (79. 1%) patients had no signs of either cellular or humoral response and were considered SARS-CoV-2-naïve. After vaccination, naïve patients who developed either humoral or cellular response were finally 65. 0%, of which 29. 9% developed either IgG or IgM and 35. 0% S-ELISpot positivity. Factors associated with vaccine unresponsiveness were diabetes and treatment with anti-thymocytes globulins during the last year. Side effects were consistent with that of the pivotal trial and no DSAs developed after vaccination. In conclusion, mRNA-1273 SARS-CoV-2 vaccine elicits either cellular or humoral response in almost two thirds of KTRs.
Drets:	Tots els drets reservats.
Llengua:	Anglès
Document:	Article ; recerca ; Versió acceptada per publicar
Matèria:	Clinical research/practice ; Infection and infectious agents-viral ; Infectious disease ; Kidney transplantation/nephrology ; Vaccine
Publicat a:	American Journal of Transplantation, Vol. 21 Num. 5 (may 2021) , ISSN 1600-6143

DOI: 10.1111/ajt.16701
PMID: 34036720

27 p, 24.6 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats